MedTrace Logo

Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry

NCT04907240 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 614

Last updated 2026-02-02

No results posted yet for this study

Summary

Collect real-world post-market clinical follow-up data on patients treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)

Conditions

Interventions

DEVICE

GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)

Intent to treat with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) in the treatment of Peripheral Artery Disease as part of routine clinical practice.

Sponsors & Collaborators

  • W.L.Gore & Associates

    lead INDUSTRY

Principal Investigators

  • Michel Reijnen, MD, PhD · Rijnstate Hospital, Arnhem, The Netherlands

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-09
Primary Completion
2026-10-31
Completion
2035-10-31

Countries

  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04907240 on ClinicalTrials.gov